In brief
An Australian study of over 400 breast‑cancer biopsies shows that increased CDK1 activity is linked to poorer outcomes in estrogen receptor‑positive patients, suggesting the protein could become a biomarker for tailoring treatment with CDK4/6 inhibitors. The findings are preliminary; larger clinical trials are required to confirm CDK1’s predictive value and to explore new drugs targeting it.
On October 31, 2026 Xinhua reported that scientists at Australia’s Garvan Institute of Medical Research have identified a protein that may help determine which estrogen‑receptor positive (ER+) breast cancers will respond to CDK4/6 inhibitors, a common class of targeted drugs.
The team examined more than 400 biopsy samples from patients with ER+ breast cancer, the most frequent subtype of the disease. They measured the activity of CDK1, a protein that drives cell division, and found that its activity rises as the cancer becomes more aggressive.
Higher CDK1 activity correlated with worse patient outcomes, the researchers said, indicating that tumors with prominent CDK1 function may be less likely to respond to the current combination therapy that pairs CDK4/6 inhibitors with hormone treatment.
Potential for Personalized Therapy
“Tracking a protein that drives cell division could help doctors tell which breast cancers are likely to respond to CDK4/6 inhibitors,” the Garvan Institute statement read, according to Xinhua. The study was published in the journal Advanced Science, suggesting that CDK1 could serve as a biomarker for more personalized treatment decisions.
If CDK1 proves to be a reliable predictor, clinicians could identify patients who are unlikely to benefit from the existing therapy early in their care, potentially steering them toward alternative options or clinical trials.
Need for Larger, Prospective Trials
The researchers emphasized that their findings need confirmation in larger groups of patients actively treated with CDK4/6 inhibitors, and that future studies should investigate whether targeting CDK1 directly might improve patient outcomes.
“The findings need to be tested in larger groups of patients treated with CDK4/6 inhibitors, and could eventually open the door to new drugs targeting CDK1,” the researchers noted, indicating the current evidence is correlative rather than causal.
In addition, the study did not assess how CDK1 activity interacts with other biomarkers, such as HER2 status or genomic signatures, meaning clinicians lack guidance on how to integrate CDK1 testing into existing treatment frameworks.
Unresolved Questions
Key questions remain: (1) Is elevated CDK1 activity a cause or consequence of aggressive tumor behavior? (2) How does CDK1 interact with the pharmacodynamics of CDK4/6 inhibitors at the molecular level? (3) Can therapeutic interventions that specifically target CDK1 improve survival in patients who fail standard therapy?
Future work must also address how best to measure CDK1 activity in clinical specimens—whether through immunohistochemistry, RNA sequencing, or other assays—and whether such tests would be cost‑effective and reproducible across laboratories.
Until these uncertainties are resolved, healthcare providers cannot rely on CDK1 activity to guide therapeutic decisions or to predict resistance to CDK4/6 inhibitors in breast‑cancer patients.
Thus, while the Garvan Institute’s research opens an intriguing avenue for biomarker discovery, the field awaits confirmation from larger, prospective trials and mechanistic studies before CDK1 can be embraced in routine clinical practice.
